Accelerating Australia is a national consortium of 21 biomedical research institutions, universities, healthcare providers and companies.
We boost biomedical entrepreneurship and translation of medical research through experiential entrepreneurial courses, brokerage and early stage commercialisation support services for our members.
We stand together. Team Accelerating Australia collaborates across sectors, organisations and disciplines to identify and reduce hurdles in our biomedical translation ecosystem to the benefit of all.
Our people are experienced research, clinical and industry professionals who are passionate about impact, innovation, knowledge, best practice and partnerships.
Most of all we believe in the ability of Australia to turn its leading biomedical research into new patient benefits, quality products and thriving companies.
Our universities and medical research institutes are carrying out world leading research. How can the clinical and economic impact of that research be realised more effectively?
Our society continues to suffer from unmet clinical needs. How do we better understand those needs so that we can strategically direct research towards addressing them, while maintaining the ‘blue sky’ research that may address future problems we have not even thought of yet?
The medical technologies and pharmaceuticals (MTP) industry has a critical role in both translating research and addressing needs. How do we improve researcher and clinician engagement with industry to enable this?
Hackathons, boot camps, accelerators and incubators, all offering to train people in innovation but how are they different and how do people know which is most appropriate for them? This is particularly important for the MTP sector as it is a highly technical and regulated environment.
Accelerating Australia supports several education/accelerator style programs in the MedTech/Pharma sector. All of these programs have a strong focus on experiential learning for participants, no matter what organisation they come from. These include:
The MIME SPARK program at Monash University which matches clinician unmet needs with Monash researchers to create real life solutions.
Accelerating Australia does not seek to duplicate the activities of others in the medical technologies and pharmaceuticals space. Rather it seeks to understand, map and complement them with the activities it directly supports, facilitating flow between different parts of the ecosystem to the benefit of all.
Accelerating Australia connects innovative ideas with the expertise and partners required to help bring these ideas closer to commercial and clinical realisation. These connections may come from inside or outside of the Accelerating Australia member base; the consortium’s aim is to leverage the full breadth of all connections for the benefit of all.
The expertise of Accelerating Australia’s core personnel, executive and mentor network spans industry and academia. They leverage this expertise for the purposes of advocacy and education to bridge the gaps between innovative ideas, proof of concept and commercial reality.
For this purpose, Accelerating Australia provides advisory sessions to those who have a startup idea or existing startup business in the MedTech/Pharma industry and are unsure of next steps.
Medical researchers and engineers
working in a university or medical research institute are likely to have excellent knowledge of their chosen research field, as well as mentorship with respect to publishing papers, presenting at conferences and obtaining research grants. However, it is unlikely that they will have much interaction with mentors of, or have specific training in, how to translate their research out of the laboratory along the path to commercial and/or clinical impact, or be exposed to industry/clinical needs.
for example doing their MBA in a university business school or working for a management consulting firm, are likely to have extensive expertise in business management, but they may not have foundational knowledge of scientific/engineering research or understanding of clinical questions.
working in a hospital will have frequent exposure to clinical needs, but they often don’t have the foundational knowledge of highly technical scientific/engineering solutions or the commercialisation pathways required to address these needs.
Industry and the Healthcare System
will benefit from having research move further along the translation pathway to points where they can engage, facilitate and benefit from medical innovation. Furthermore they will benefit from researchers focusing on addressing industry and clinical needs, whether with short, medium or long-term solutions.
Members of the Community
suffering from ill health, through to those funding medical research through the taxes they pay and donations they give, are all keen to see improved translation of medical research that has greater impact in a more timely manner.